Physician profile
Jie Wang
NPI 1215257183
$18,816.39
in general payments reported to CMS, 2019-2025
16 companies · $4,167 in 2025
The $4,167 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,736 · 2020: $5,240 · 2022: $251 · 2023: $208 · 2024: $4,215 · 2025: $4,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,480 · Food and Beverage: $1,322 · Travel and Lodging: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,479.69 |
| Food and Beverage | $1,322.31 |
| Travel and Lodging | $787.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $7,588.80 | 2022-2025 | Beleodaq |
| Kyowa Kirin, INC. | $5,749.30 | 2020-2025 | Poteligeo |
| Verastem, INC. | $4,650.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 2025 | Reblozyl |
| Pfizer INC. | $112.77 | 2024 | |
| Cti Biopharma Corp. | $108.71 | 2023 | Vonjo |
| Seagen INC. | $94.51 | 2022 | |
| Genentech USA, INC. | $85.00 | 2019 | |
| Sobi, INC | $82.88 | 2023 | |
| Beigene USA, INC. | $78.00 | 2024 | Brukinsa |
| Btg International INC. | $77.75 | 2025 | Voraxaze |
| Celgene Corporation | $52.95 | 2025 | Breyanzi |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.